TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers

Abstract Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in...

Full description

Bibliographic Details

Published in:	Cell Death and Disease
Main Authors:	Helene Damhofer, Tülin Tatar, Benjamin Southgate, Scott Scarneo, Karl Agger, Daria Shlyueva, Lene Uhrbom, Gillian M. Morrison, Philip F. Hughes, Timothy Haystead, Steven M. Pollard, Kristian Helin
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-04-01
Online Access:	https://doi.org/10.1038/s41419-024-06654-1